Matthew Jay Budoff, MD, FACC, FAHA, is a professor of medicine at David Geffen School of Medicine at UCLA and the Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center. Dr. Budoff is a graduate of University of California at Riverside (BS) and graduated a member of Alpha Omega Alpha from George Washington University School of Medicine (MD). He completed his training in internal medicine and his cardiology fellowship at Harbor-UCLA Medical Center. Dr. Budoff is on the editorial boards of several cardiology journals, including Clinical Cardiology, Journal of Invasive Cardiology, JACC: Cardiovascular Imaging, and Cardiovascular Diabetology. Dr. Budoff has served on a number of association committees, including as secretary and executive committee member for LA BioMed (2018–current), foundation board member of the American College of Cardiology (ACC; 2014–current), and member of the ACC Annual Scientific Session program committee (2013–2015). He also serves on the executive committee of the ACC Center of Excellence on Cardiovascular Risk Reduction (2018-2020).
Dr. Budoff has author or coauthored more than 50 books and book chapters and more than 1700 articles and abstracts. He has received numerous research grants from the National Institutes of Health and has been invited to lecture at cardiology conferences around the world. In addition to his 2015 appointment as the Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center, he has been recognized for his work by the Society of Cardiovascular Computed Tomography, from which he received the Gold Medal Award and recently designated as Master of the Society of Cardiovascular Computed Tomography (MSCCT), and has been inducted into the European Academy of Sciences. Dr. Budoff has been named to “America’s Top Doctors” for each of the past 9 years. In 2011, he was named a US News Top Doctor for cardiology, was awarded the Albert Nelson Marquis Lifetime Achievement Award in 2018 and named to “The world’s most influential scientific researchers” in 2018 and 2019.
Matthew Jay Budoff, MD, FACC, FAHA
David Geffen School of Medicine at UCLA — Los Angeles, California
By Matthew Jay Budoff,
MD, FACC, FAHA
David Geffen School of Medicine at UCLA Los Angeles, California
As we move into the next decade and beyond, a strong shift will occur from intervention to prevention. Not only driven by Courage, Orbita and Ischemia Trials, but by the understanding that treating the vulnerable patient is more important than treating the vulnerable plaque. Risk stratification will continue to improve, shifting from ACC/AHA Pooled Cohort ‘population’ based stratification to personalized medicine, with coronary artery calcium scanning, personal monitoring devices and genotyping leading the way. This allows physicians to identify the person who has disease, as compared to the person who may be at increased risk of developing the disease. This approach is not only well proven, but advocated by our more recent Cholesterol and Prevention Guidelines from the ACC and AHA.
Based on multiple outcome studies and results from the ISCHEMIA Trial, we will shift from ischemia based testing (stress nuclear, echocardiography) to anatomical based testing (CT angiography) to assess the presence of left main and subclinical atherosclerosis. This will improve outcomes, as seen in the SCOT-HEART Trial, and improve yield of obstructive disease in the cardiac cath lab.
Finally, cardiology will see a new specialty, cardiometabolic medicine, develop, ushering in a new age of advanced diabetes treatment to improve cardiovascular outcomes. This has taken too long, as cardiovascular disease claims the lives of 2/3 of our patients with diabetes, and new therapies, such as SGLT-2 inhibitors and GLP-1 receptor agonists, are implemented by cardiology and nephrology with increasing frequency.
